T. Rowe Price Associates, Inc. 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | T. Rowe Price Associates, Inc. | 4,074,144 3.300% | -2,461,224 (-37.66%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | T. Rowe Price Associates, Inc. | 6,535,368 5.400% | 2,859,543 (+77.79%) | Filing |